C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 403/06 (2006.01) A61K 31/415 (2006.01) C07D 233/61 (2006.01) C07D 521/00 (2006.01)
Patent
CA 2182583
This invention relates to the novel enantiomerically pure dextroratory isomer of liarozole of formula (I) and the pharmaceutically acceptable acid addition salt forms thereof. These compounds are particularly useful in treating disorders which arecharacterized by an increased proliferation and/or abnormal differentiation of normal, preneoplastic or neoplastic epithelial cells. These compounds are particularly useful in the field of dermatology. Also disclosed are compositions containing said novel compounds, methods of preparing said novel compounds as well as methods of usingthe mentioned compounds to treat the mentioned disorders.
L'invention se rapporte à un nouvel isomère dextrogyre, pur sur le plan énantiomorphe, de liarozole de la formule (I) ainsi qu'aux formes pharmacologiquement acceptables des sels d'addition acide de celui-ci. Ces composés sont particulièrement utiles dans le traitement des affections caractérisés par une prolifération accrue et/ou une différentiation anormale des cellules épithéliales normales, prénéoplasiques ou néoplasiques. Ces composés sont particulièrement utiles dans le domaine de la dermatologie. L'invention se rapporte également à des compositions contenant ces nouveaux composés, aux procédés de préparation de ceux-ci ainsi qu'aux méthodes d'utilisation desdits composés dans le traitement des affections mentionnées.
Gowling Lafleur Henderson Llp
Janssen Pharmaceutica Naamloze Vennootschap
LandOfFree
Enantiomerically pure (+)-liarozole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enantiomerically pure (+)-liarozole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enantiomerically pure (+)-liarozole will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1989923